Search results
Results from the WOW.Com Content Network
Thailand Food and DrugAdministration (FDA) on Monday gave emergency use authorisationfor the COVID-19 vaccine of Sinovac Biotech, paving theway for the country's first coronavirus inoculations.
In September 2020, Sinovac began Phase I–II trials in China on children and adolescents ages 3–17. [92] In May 2021, Sinovac began Phase IIb trials in China with 500 participants for children and adolescents 3–17 years old. [93] In June 2021, it was announced that the vaccine was safe and immunogenic in this age group. [94]
The World Health Organization (WHO) said on Tuesday it has approved a COVID-19 vaccine made by Sinovac Biotech for emergency use listing, paving the way for a second Chinese shot to be used in ...
Offering Sinovac Biotech COVID-19 vaccines to the public in Singapore for the first time since Friday, several private clinics reported overwhelming demand for the Chinese-made shot, despite ...
Singapore also received its first shipment of Sinovac Biotech's CoronaVac vaccine, on 22 December 2020. However, the vaccine was not authorised for use by the Health Sciences Authority (HSA). [ 12 ] [ 13 ] On 2 June 2021, MOH approved the Sinovac vaccine for used in private healthcare settings so people, who are not suitable to take the mRNA ...
[31] [32] [33] By April 2021, Sinovac had a production capacity of two billion doses a year [34] and had delivered 600 million total doses. [35] It is currently being manufactured at several facilities in China, [34] Brazil, [36] and Egypt. [37] On 1 June 2021, the World Health Organization (WHO) validated the vaccine for emergency use.
A spokesperson for the UN agency told Reuters that the ministry will continue to communicate with COVAX facility to receive vaccines in the coming months. North Korea rejects offer of nearly 3 ...
For the BIBP vaccine, geometric mean titers declined by 1.6-fold, from 110.9 to 70.9, which was less than antisera from mRNA vaccine recipients with a 6-folds decrease. [50] Preliminary clinical data from Novavax and Johnson & Johnson also showed they were less effective in preventing COVID-19 in South Africa, where the new variant is widespread.